Trial NCT04543409

View at ClinicalTrials.gov 
Org. Study IDs: D3255C00001
Secondary IDs: 2019-002871-32

Last trial update was posted on 2023-11-18

MeSH Interventions

Benralizumab

MeSH Conditions

Eosinophilic Esophagitis Esophagitis

Other Conditions


Stopping Reasons

High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints. Given the lack of clear benefit in this patient population, study has been terminated.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID